ClinicalTrials.gg

Program

Pioglitazone

Also written as “pioglitazone”, “Pioglitazone 30 mg” and “Pioglitazone and azilsartan”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Alzheimer Disease · Fatty Liver · Peripheral Arterial Disease, led by 10 companies.

Furthest: phase 4, since Jun 27, 200752 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda330 open or runningphase 4since Jun 27, 2007Sep 9, 2005none ahead
Boryung Pharmaceutical42 open or runningphase 3since May 9, 2021May 9, 2021none ahead
Merck40 open or runningphase 3since Jul 22, 2008Aug 2, 2007none ahead
GlaxoSmithKline30 open or runningphase 4since Apr 2, 2009Dec 22, 2005none ahead
Hoffmann-La Roche20 open or runningphase 4since Oct 16, 2007Oct 16, 2007none ahead
Viatris20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
dr-muhammad-abdulghani10 open or runningno phasesince Aug 16, 2016Aug 16, 2016none ahead
getz-pharma10 open or runningphase 4since Jul 19, 2021Jul 19, 2021none ahead
Medtronic10 open or runningearly phase 1since Jul 21, 2008Jul 21, 2008none ahead
strekin-ag10 open or runningphase 3since Nov 1, 2017Nov 1, 2017none ahead

Also a collaborator on its studies: parexel, zinfandel-pharmaceuticals-inc, Eli Lilly and takeda-pharmaceuticals-north-america-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 37 studies since Sep 9, 2005.

  1. Feb 1, 2011Phase 3 study in Diabetes Mellitus, Type 2Takeda · NCT01289119 · 506 enrolled · China, Hong Kong, Taiwan
  2. Sep 7, 2011Phase 1 study in Non-alcoholic Fatty Liver DiseaseMerck · NCT01431521 · 31 enrolled
  3. Oct 18, 2011Phase 1 study in HealthyTakeda · NCT01456117 · 61 enrolled · United States
  4. Aug 31, 2012Phase 4 study in Diabetes MellitusTakeda · NCT01686711 · 207 enrolled · Japan
  5. Aug 26, 2013Phase 3 study in Mild Cognitive Impairment Due to Alzheimer's DiseaseTakeda · NCT01931566 · 3,494 enrolled · United States, Australia, Germany and more
  6. Oct 24, 2013Phase 4 study in Diabetes Mellitus, Type 2Takeda · NCT01972724 · 114 enrolled · Korea, Republic of
  7. Nov 4, 2014Phase 3 study in Mild Cognitive Impairment Due to Alzheimer's DiseaseTakeda · NCT02284906 · 40 enrolled · United States, Australia, Switzerland and more
  8. Feb 19, 2015Phase 1 study in AnemiaGlaxoSmithKline · NCT02371603 · 70 enrolled · United States
  9. Aug 16, 2016dr-muhammad-abdulghani's first study: no phase study in Diabetes Mellitus, Type 2New to dr-muhammad-abdulghanidr-muhammad-abdulghani · NCT02887625 · 410 enrolled · Qatar
  10. Nov 1, 2017strekin-ag's first study: phase 3 study in Acute Hearing LossNew to strekin-agstrekin-ag · NCT03331627 · 165 enrolled · Czechia, Germany, Switzerland
  11. May 9, 2021Boryung Pharmaceutical's first study: phase 3 study in Type2 DiabetesNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT04885712 · 378 enrolled · Korea, Republic of
  12. Jul 19, 2021getz-pharma's first study: phase 4 study in Diabetes Mellitus, Type 2New to getz-pharmagetz-pharma · NCT04976283 · 123 enrolled · Pakistan
  13. May 26, 2022Phase 1 study in Diabetes Mellitus, Type 2Boryung Pharmaceutical · NCT05411965 · 48 enrolled · Korea, Republic of
  14. Jul 16, 20252 phase 1 studies in Diabetes MellitusBoryung Pharmaceutical · NCT07083401, NCT07083388

TargetBeta

PPARG →read by rule
“Peroxisome proliferator-activated receptor gamma agonist”ChEMBL 37, by rule

Other programs on PPARG

ProgramCompanyFurthest phaseStudies
saroglitazarruleZydus Lifesciencesphase 419
chiglitazarruleChipscreen Biosciencesphase 39
lanifibranorinventiva-pharmaphase 36
T3D-959rulet3d-therapeutics-incphase 33

Studies

All 52 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07083401Diabetes Mellitus · South Korea1RecruitingBoryung PharmaceuticalJul 5, 202640
NCT07083388Diabetes Mellitus · South Korea1RecruitingBoryung PharmaceuticalJul 3, 202652
NCT05411965Diabetes Mellitus, Type 2 · Korea, Republic of1CompletedBoryung PharmaceuticalJul 3, 202248
NCT04976283Diabetes Mellitus, Type 2 · Pakistan4UNKNOWNgetz-pharmaMay 15, 2023123
NCT04885712Type2 Diabetes · Korea, Republic of3CompletedBoryung PharmaceuticalSep 19, 2022378
NCT03331627Acute Hearing Loss · Czechia, Germany, Switzerland3Completedstrekin-agFeb 6, 2020165
NCT02887625Diabetes Mellitus, Type 2 · Qatar–UNKNOWNdr-muhammad-abdulghaniMay 2017410
NCT02371603Anemia · United States1CompletedGlaxoSmithKlineAug 12, 201570
NCT02284906Mild Cognitive Impairment Due to Alzheimer's Disease · United States, Australia, Switzerland and more3TerminatedTakedaJan 31, 201840
NCT01972724Diabetes Mellitus, Type 2 · Korea, Republic of4CompletedTakedaOct 17, 2016114
NCT01931566Mild Cognitive Impairment Due to Alzheimer's Disease · United States, Australia, Germany and more3TerminatedTakedaJul 24, 20183,494
NCT01686711Diabetes Mellitus · Japan4CompletedTakedaDec 2013207
NCT01456117Healthy · United States1CompletedTakedaJul 201261
NCT01431521Non-alcoholic Fatty Liver Disease1CompletedMerckSep 18, 201231
NCT01289119Diabetes Mellitus, Type 2 · China, Hong Kong, Taiwan3CompletedTakedaDec 2011506
NCT01124656Diabetes Mellitus, Type 23TerminatedTakedaMay 200726
NCT01115712Overweight1CompletedMerckSep 201035
NCT00879970Diabetes Mellitus, Type 2 · United States, Argentina, Canada and more4TerminatedGlaxoSmithKlineNov 20101,332
NCT00771004Coronary Artery Disease · Germany2CompletedTakedaFeb 200963
NCT00770952Diabetes Mellitus · Germany3CompletedTakedaDec 200891
NCT00770653Diabetes Mellitus · Germany3CompletedTakedaMay 2009305
NCT00770640Diabetes Mellitus · Germany2CompletedTakedaJun 201040
NCT00770575Cardiovascular Diseases2CompletedTakedaOct 2006148
NCT00770497Inflammation · Germany2CompletedTakedaMay 2008172
NCT00770445Diabetes Mellitus · Germany4CompletedTakedaJul 2010121
NCT00772174Diabetes Mellitus3CompletedTakedaFeb 2008418
NCT00770835Diabetes Mellitus · Italy4CompletedTakedaMay 201139
NCT00762736Diabetes Mellitus · United States, Argentina, Chile and more2CompletedTakedaOct 2005704
NCT00754403Diabetes Mellitus4CompletedTakedaOct 2006312
NCT00744367Diabetes Mellitus, Type 2 · United States, Brazil, Canada and more3CompletedHoffmann-La RocheNov 2010326
NCT00727857Diabetes Mellitus · United States, Chile, Mexico and more3CompletedTakedaAug 2008600
NCT00722917Diabetes Mellitus · United States2TerminatedTakedaApr 2009323
NCT00722371Diabetes Mellitus, Type 23CompletedMerckOct 26, 20101,615
NCT00720577Peripheral Arterial DiseaseEarly 1CompletedMedtronicJul 2007164
NCT00708175Glucose Metabolism Disorders · United States4CompletedTakedaJan 2011156
NCT00676260Diabetes Mellitus · United Kingdom2CompletedTakedaAug 200429
NCT00672919Diabetes Mellitus · United States, Puerto Rico4CompletedTakedaAug 2004305
NCT00649558Healthy · United States1CompletedViatrisMar 200336
NCT00649012Healthy · United States1CompletedViatrisMar 200340
NCT00545233Hepatitis C, Chronic · United States, Puerto Rico4CompletedHoffmann-La RocheDec 2010155
NCT00521820Diabetes Mellitus3TerminatedTakedaOct 2003518
NCT00521742Diabetes Mellitus3CompletedTakedaJan 2003300
NCT00511108Diabetes Mellitus, Type 21CompletedMerckFeb 24, 2009211
NCT00494312Diabetes Mellitus4CompletedTakedaJun 20052,120
NCT00395512Diabetes Mellitus · United States, Argentina, Australia and more3CompletedTakedaFeb 2008655
NCT00376181Diabetes Mellitus, Type 2 · United States, Argentina, Chile and more3TerminatedTakedaMay 200796
NCT00331487Diabetes Mellitus · United States3CompletedTakedaMar 2004719
NCT00328627Diabetes Mellitus, Type 2 · United States, Australia, Brazil and more3CompletedTakedaMar 20081,554
NCT00269061Diabetes Mellitus, Type 2 · United States1CompletedGlaxoSmithKline32
NCT00225277Diabetes Mellitus · United States, Argentina, Canada and more3CompletedTakedaOct 2007547
NCT00225264Diabetes Mellitus · United States3CompletedTakedaMay 2006458
NCT00174993Diabetes Mellitus · Austria, Belgium, Czech Republic and more3CompletedTakedaJan 20054,373

How it is read

Names in the registry

  • “Pioglitazone”, 33 entries
  • “pioglitazone”, 5 entries
  • “Pioglitazone 30 mg”, 4 entries
  • “Pioglitazone and azilsartan”, 4 entries
  • “TAK-379”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.